Recently, the combination of AZD0364, a selective Erk1/2 inhibitor, and selumetinib has been shown to alleviate tumor progression in multiple xenograft models of KRAS-mutant NSCLC [139]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.